 |
Previous Article | Next Article 
The Journal of Neuroscience, April 15, 2000, 20(8):2926-2933
Circulating Insulin-Like Growth Factor I Mediates Effects of
Exercise on the Brain
Eva
Carro1,
Angel
Nuñez2,
Svetlana
Busiguina1, and
Ignacio
Torres-Aleman1
1 Laboratory of Neuroendocrinology, Cajal Institute,
Consejo Superior de Investigaciones Cientificas, 28002 Madrid,
Spain, and 2 Department of Morphology, School of
Medicine, Autonoma University, 28029 Madrid, Spain
 |
ABSTRACT |
Physical exercise increases brain activity through mechanisms not
yet known. We now report that in rats, running induces uptake of blood
insulin-like growth factor I (IGF-I) by specific groups of neurons
throughout the brain. Neurons accumulating IGF-I show increased
spontaneous firing and a protracted increase in sensitivity to afferent
stimulation. Furthermore, systemic injection of IGF-I mimicked the
effects of exercise in the brain. Thus, brain uptake of IGF-I after
either intracarotid injection or after exercise elicited the same
pattern of neuronal accumulation of IGF-I, an identical widespread
increase in neuronal c-Fos, and a similar stimulation of hippocampal
brain-derived neurotrophic factor. When uptake of IGF-I by brain cells
was blocked, the exercise-induced increase on c-Fos expression was also
blocked. We conclude that serum IGF-I mediates activational effects of
exercise in the brain. Thus, stimulation of the uptake of blood-borne
IGF-I by nerve cells may lead to novel neuroprotective strategies.
Key words:
insulin-like growth factor I; exercise actions on brain
function; blood-CSF pathway; neuronal activation; c-Fos; brain-derived
neurotrophic factor
 |
INTRODUCTION |
The roman aphorism "mens sana in
corpore sano" acknowledges the well recognized positive effects of
physical exercise on brain function. Recent evidence links physical
activity to diverse indicators of neuronal function such as increased
expression of neurotrophic factors, early response genes, or
hippocampal neurogenesis (Neeper et al., 1995 ; Iwamoto et al., 1996 ;
Gomez-Pinilla et al., 1997 ; Van Praag et al., 1999 ). However, the
mechanisms underlying these changes are not yet known.
Insulin-like growth factor I (IGF-I) is a trophic factor that
circulates at high levels in the blood-stream and mediates many of the
effects of growth hormone (GH) in the body (Jones and Clemmons, 1995 ).
Although the main source of serum IGF-I is the liver (Yakar et al.,
1999 ), many other tissues synthesize it and are sensitive to its
trophic actions (Jones and Clemmons, 1995 ). In the adult brain,
expression of IGF-I mRNA is circumscribed to specific locations (Werther et al., 1990 ), whereas IGF-I and its receptor are widespread and distributed throughout the CNS (Bondy et al., 1992 ).
The CSF contains IGFs and IGF-binding proteins (IGFBPs) (Ferry
et al., 1999 ). However, epithelial cells producing the CSF in the
choroid plexus (CP) do not express detectable levels of IGF-I mRNA,
although they contain high levels of IGF-I receptor (Marks et al.,
1991 ; Werther et al., 1990 ). These observations suggest that
IGF-I from an external source may enter into the brain through the CSF
pathway. Indeed, previous evidence indicates that peripheral IGF-I
enters into the brain (Reinhardt and Bondy, 1994 ) and that IGF-I
delivered into the CSF is taken up by brain cells (Fernandez-Galaz et
al., 1998 ).
If entrance of IGF-I into the brain is of any biological relevance, it
must take place under physiological conditions. In this regard, it has
already been reported that peripuberal surges in blood IGF-I levels
(Handelsman et al., 1987 ) modulate hypothalamic function (Hiney et al.,
1996 ). Because another stimulus of the GH-IGF-I axis is physical
exercise (Schwarz et al., 1996 ), we hypothesized that blood IGF-I may
also modulate brain responses to physical activity. Thus, we explored
whether circulating IGF-I enters into the brain during exercise and
whether this entrance impinges on neuronal function.
 |
MATERIALS AND METHODS |
Experimental procedures. Adult Wistar rats were
injected either in the carotid artery (intracarotid) or in the lateral
cerebral ventricle (intracerebroventricularly) under
pentobarbital anesthesia (50 mg/kg, i.p.) with
digoxigenin-labeled IGF-I (DIG-IGF-I). Human recombinant IGF-I
(GroPep) was labeled with
digoxigenin-3-O-methylcarbonyl-aminocaproic acid-N-hydroxy-succinimide ester (Boehringer
Mannheim, Mannheim, Germany) by a procedure that renders a fully
bioactive IGF-I (Fernandez-Galaz et al., 1998 ). For
intracarotid injection, DIG-IGF-I (10 µg/rat in 100 µl saline) was
injected through a cannula placed in the common carotid artery. For
intracerebroventricular administration, the cannula was implanted
stereotaxically into the lateral cerebral ventricle [coordinates: 1
mm anteroposterior (A) from bregma, 4 mm ventral (V), and 1.2 mm
lateral (L) (Paxinos and Watson, 1997 )]. In blocking experiments,
DIG-IGF-I (10 µg) was given simultaneously with excess unlabeled
IGF-I (100 µg) or excess insulin (2 mg). Controls were injected with
saline. To inhibit brain uptake of IGF-I, animals received for 3 d
an intracerebroventricular infusion containing an anti-IGF-I polyclonal
antibody (20% in saline) plus an IGF-I receptor antagonist (20 µg/ml). The anti-IGF-I polyclonal antibody was produced by us and
shows very high binding affinity for IGF-I, whereas the IGF-I receptor
antagonist known as JB-1 has been shown by us and others to inhibit the
action of IGF-I both in vivo and in vitro
(Fernandez et al., 1997 ). As shown in Figure
1D, this procedure resulted in complete blockade of
the entrance of IGF-I into the brain, because no IGF-I labeling was found. Control animals received saline infusions.
Growth factor assays. IGF-I levels were determined by
radioimmunoassay (RIA) (Pons and Torres-Aleman, 1992 ). To avoid
contamination of serum IGF-I with brain IGF-I measurements, rats were
thoroughly perfused with saline to eliminate blood from brain tissue.
CSF samples (150 µl) were obtained from the cisterna magna. IGF-I mRNA levels were determined with an RNase protection assay
(Busiguina et al., 1996 ). In situ hybridization for BDNF was
performed with probes generated with a rat BDNF cDNA cloned in
pSK (Busiguina et al., 1996 ).
Treadmill running. Animals were familiarized with the
treadmill apparatus (Letica) to minimize novelty stress and then
divided in two groups: exercised and nonexercised. The electrical shock system that encouraged the animals to run was then disconnected to
avoid pain stress. The exercise group ran for 1 hr at 17 m/min, whereas
the control group remained in the treadmill without running. Animals
bearing intracerebroventricular minipumps to block IGF-I uptake ran
under identical conditions. After running, the rats were deeply
anesthetized and killed. Trunk blood samples were obtained, and brains
were perfused (for immunocytochemistry or RIA) or snap frozen (for RNA quantitation).
Immunocytochemistry. Immunocytochemical detection was
performed as described (Fernandez et al., 1999 ). The primary antibodies used were polyclonal anti-IGF-I (1:500), polyclonal (1:300) or monoclonal (1:200) anti-digoxigenin (Boehringer Mannheim); polyclonal anti-IGF-I receptor (1:1000), monoclonal anti-c-Fos (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA); and monoclonal anti-calbindin (1:1000) (Swant). The secondary antibodies that were used were biotinylated goat anti-mouse IgG (1:1000) (Jackson ImmunoResearch, West
Grove, PA) or anti-rabbit IgG (1:250-1:1000) (Pierce, Rockford, IL). A
third amplification step was used with Cy3-streptavidin (1:1000)
(Jackson ImmunoResearch). For double immunocytochemistry, the rabbit
and mouse primary antibodies were added simultaneously. In this case,
secondary antibodies were a goat anti-rabbit IgG-Cy2 and a goat
anti-mouse IgG-Cy5 (1:250) (Amersham, Arlington Heights, IL). Sections
were visualized in a confocal microscope (Leica, Nussloch, Germany).
Neuronal recordings. Rats of both sexes (180-250 gm) were
anesthetized with either urethane (1.6 gm/kg i.p.; 50% of the animals) or ketamine hydrochloride/xylazine (100 and 20 mg/kg i.p.,
respectively) to discard interferences of the anesthesia with
experimental procedures. Animals were placed in a stereotaxic device,
with control of end-tidal CO2 concentration. For
electroencephalogram (EEG) recording, a macroelectrode (120 µm
diameter) was lowered 1.5 mm from the cortical surface into the frontal
lobe. The EEG was filtered between 0.3 and 30 Hz and continuously
monitored in the oscilloscope. Single unit recordings were performed in
the dorsal column nuclei (DCN; n = 12 rats) and in the
Purkinje cellular layer of the cerebellum (n = 11) by
means of tungsten microelectrodes (World Precision Instruments).
Microelectrodes were aimed at the gracilis [A, 13.6 to 14.6 mm
from bregma; L, 0.2-1.0 mm; V, 0.0-0.5 mm from the surface of the
brain (Paxinos and Watson, 1997 )] or the cuneatus nuclei [A, 13.5
to 14.5 from bregma; L, 1.5-2.5 mm; V, 0.0-0.5 mm from the surface
of the brain (Paxinos and Watson, 1997 )]. Cerebellar recordings were
performed in the vermis. The vermis was exposed and covered with warmed
mineral oil. Unit recordings (0.3-3 kHz) and field potentials (1 Hz to
3 kHz) were filtered, amplified, and fed to a Macintosh computer
(sample frequency 10 kHz) for off-line analysis. Somatosensory
stimulation of DCN cells was performed by an electronically gated probe
(1 mm diameter, 20 msec duration) delivered at 0.5 Hz on either the
forelimbs or hindlimbs. Parallel fiber electrical stimulation was
performed with a bipolar electrode placed on the cerebellar surface
(50-100 µA; 0.1-0.3 msec). Statistical analysis of the recorded
signals was performed with Spike 2 software (Cambridge Electronic
Design). Summed peristimulus time histograms (PSTHs) were
calculated, using 2 msec bin widths. Averages of the cerebellar field
potentials evoked by parallel fiber stimulation were also calculated.
All data are shown as mean ± SE. Statistical analysis was performed with a nonparametric Wilcoxon test. All experiments were performed in
accordance with European Community Council regulations.
 |
RESULTS |
Systemic injection of IGF-I mimics the effects of exercise on
the brain
Because protective actions of blood-borne IGF-I were found in
brain-injured rats (Fernandez et al., 1998 ), we determined whether passage of blood IGF-I into the brain would also take place under physiological conditions such as during exercise-induced activation of
the GH-IGF-I axis. As shown in Figure
1A, 1 hr of treadmill running induced profuse labeling of different brain areas with IGF-I,
whereas nonexercised control animals show no brain IGF-I labeling (Fig.
1B,a). IGF-I-positive cells were
found in areas of the cortex, hippocampus, striatum, septum, thalamus,
hypothalamus, cerebellum, red nucleus, and several brain stem nuclei
(most prominently the inferior olive, reticular, and gracilis and
cuneatus nuclei). Most cells accumulating IGF-I are calbindin positive
(Fig. 2A), which
together with their typical neuronal morphology makes us consider them
as neurons.

View larger version (61K):
[in this window]
[in a new window]
|
Figure 1.
Physical exercise and intracarotid injection of
IGF-I produce similar effects in the brain. A, The same
brain areas show labeling of neurons with IGF-I after treadmill running
(a-c) and intracarotid injection of IGF-I
(d-f). Three representative areas are shown.
Nonexercised, saline-injected rats show almost undetectable brain IGF-I
staining (B). Str, Striatum;
Cx, cerebral cortex; RN, red nucleus.
Biotinylated anti-rabbit IgG followed by Cy3-streptavidin was used
after incubation with a polyclonal anti-IGF-I antibody.
B, Digoxigenin (DIG) and IGF-I colocalize
within the same neurons after intracarotid injection of DIG-IGF-I. A
representative field in the brainstem is shown. a, Low
magnification (10×) of IGF-I staining in the inferior olive nucleus
(IO) of a saline-injected rat. Note the absence of
signal. Inset, Higher magnification (40×) of the IO
field. b, The same field showing IGF-I staining in an
IGF-I-injected rat. Inset, High magnification showing
IGF-I-positive cells. c, High magnification (40×) of IO
neurons stained with a monoclonal anti-DIG antibody
(green). d, The same field stained
with a polyclonal anti-IGF-I antibody (red).
e, Colocalization of DIG and IGF-I within the same IO
neurons. Scale bars: a, b, 500 µm;
c-e, 50 µm. Primary antibody
incubation was followed by an anti-rabbit Cy2 and anti-mouse Cy5,
respectively. C, Exercise or intracarotid injection of
IGF-I elicits a similar pattern of increased c-Fos staining throughout
the brain. Only the piriform cortex (Pir) is shown as a
representative area. a, Control animals show no c-Fos
staining. b, c-Fos staining after 1 hr of intracarotid
injection of IGF-I. c, c-Fos staining after 1 hr of
running. Scale bar (a-c): 500 µm.
d, Higher magnification of the field in c
showing nuclear localization of the c-Fos signal. Scale bar, 50 µm.
Arrows indicate immunoreactive cells. A monoclonal
anti-c-Fos antibody followed by a biotinylated anti-mouse IgG and
Cy3-streptavidin was used. D, Blockade of the
exercise-induced capture of IGF-I by brain cells results in absence of
c-Fos labeling after exercise. a, IGF-I labeling in the
hippocampus of a rat that ran for 1 hr. c, Chronic
intracerebroventricular delivery of a combination of an anti-IGF-I
antibody and an IGF-I receptor antagonist results in absence of IGF-I
staining after 1 hr of running exercise. Scale bar (a,
c): 50 µm. b, c-Fos staining is induced
in the hippocampus by 1 hr of running. c, No c-Fos
labeling is seen in exercised animals in which brain uptake of IGF-I is
blocked. Scale bar (b, d): 500 µm. The
hippocampus is shown as a representative area, but absence of labeling
for IGF-I and c-Fos was found in all brain areas. E,
Expression of BDNF in the hippocampus is increased by running and by
intracarotid injection of IGF-I. Control: background BDNF RNA staining
in brain slices incubated with excess unlabeled probe. Saline: animals
injected with saline show weak BDNF expression in the hippocampus.
Exercise: running induces increased expression of BDNF in the
hippocampus. IGF-I: injection of IGF-I produces a similar increase in
hippocampal expression of BDNF. Cx, Cortex;
Hy, hippocampus.
|
|

View larger version (62K):
[in this window]
[in a new window]
|
Figure 2.
Blood-borne IGF-I is taken up by brain
cells. A, Calbindin and IGF-I colocalize within neurons
after intracarotid injection of DIG-IGF-I. A representative field in
the cerebellar cortex is shown. a, Purkinje neurons
stained with a polyclonal anti-IGF-I antibody (red).
b, The same field stained with a monoclonal
anti-calbindin antibody (green).
c, Colocalization of calbindin and IGF-I within
cerebellar Purkinje cells. Primary antibody incubation was followed by
an anti-rabbit Cy2 and anti-mouse Cy5, respectively. B,
Uptake of DIG-IGF-I from serum is abolished by coinjection of excess
unlabeled IGF-I but not by excess insulin. a, Inferior
olive (IO) neurons of a rat after intracarotid injection
with DIG-IGF-I (10 µg). b, IO neurons of an animal
injected with DIG-IGF-I (10 µg) plus unlabeled IGF-I (100 µg) show
almost no immunoreactivity for digoxigenin. c,
Coinjection of insulin (2 mg) with DIG-IGF-I (10 µg) results in
partial displacement of digoxigenin label. Intracarotid injections were
performed 1 hr earlier. C, Accumulation of
DIG-IGF-I by the brain is time-dependent. A representative field of
the cerebellar cortex is shown. a, No digoxigenin
immunoreactivity is present in a saline-injected rat. Purkinje cells
(PC) in the cerebellar cortex stained for digoxigenin 5 min (b), 1 hr (c), and 3 hr
(d) after intracarotid injection of DIG-IGF-I; 6 hr (e) later, staining was absent.
GL, Granule cell layer; ML, molecular
layer. Scale bars, 50 µm. Polyclonal anti-DIG antibody followed by
biotinylated anti-rabbit IgG and Cy3-streptavidin was used.
D, Brain levels of IGF-I are increased after exercise
(p < 0.05) or after intracarotid injection
of IGF-I (p = 0.05), as compared with
control levels.
|
|
To ascertain whether exercise-induced IGF-I labeling of brain cells was
caused by uptake of IGF-I from serum, we first determined whether
systemic administration of IGF-I results also in its accumulation by
brain cells. As shown in Figure 1A, intracarotid
injection of digoxigenin-labeled IGF-I (10 µg per rat) resulted in
IGF-I staining of the same brain areas labeled with IGF-I after
physical exercise. Double-staining of the cells showed that labeled
neurons contained digoxigenin-labeled IGF-I because both IGF-I and
digoxigenin colocalized in the same neurons (Fig.
1B). Serum levels of IGF-I were not modified by
either running or intracarotid injection of IGF-I: 9 ± 0.9 ng/ml
after 1 hr of exercise (n = 6), 11.4 ± 0.4 ng/ml
after 1 hr of intracarotid injection of IGF-I (n = 6), and 8.9 ± 0.4 ng/ml in saline-injected controls
(n = 6).
Does injection of exogenous IGF-I mimic the effects of exercise on the
brain? As illustrated in Figure 1C, both exercise and intracarotid injection of IGF-I elicited the same pattern of increased c-Fos staining throughout the CNS. Colocalization analysis of c-Fos and
IGF-I indicated that only a minority of the neurons expressing c-Fos
also accumulated IGF-I (Table 1). In
addition, a similar increase in hippocampal expression of BDNF mRNA was found in animals subjected to 1 hr of treadmill running (Neeper et al.,
1995 ) and in animals receiving an intracarotid injection of IGF-I 1 hr
before being killed (Fig. 1E).
View this table:
[in this window]
[in a new window]
|
Table 1.
Brain areas with c-Fos staining that have afferent
and/or efferent projections to the corresponding areas showing IGF-I
staining
|
|
To determine whether entrance of IGF-I into the brain is a critical
intermediary of exercise actions on the brain, we blocked the uptake of
IGF-I by brain cells before animals were subjected to 1 hr of treadmill
running. Chronic administration into the CSF of an anti-IGF-I antibody
plus an IGF-I receptor antagonist (JB-1) resulted in blockade of IGF-I
entrance into the brain after exercise, as determined by absence of
brain labeling with IGF-I (Fig. 1D). Importantly,
this procedure resulted also in blockade of the exercise-induced c-Fos
staining of brain cells (Fig. 1D).
Entrance of blood-borne IGF-I into the brain
The previous results suggested that increased labeling of IGF-I in
the brain after either exercise or intracarotid injection may be caused
by increased uptake of serum IGF-I by brain cells. Thus, we determined
whether brain IGF-I levels increase after exercise or intracarotid
injection of IGF-I. As shown in Figure 2D, running
for 1 hr elicited a significant increase in brain IGF-I levels (35%
over controls, p < 0.05; n = 6),
whereas 1 hr after intracarotid injection of IGF-I (10 µg), a smaller
increase was also found (22% over controls, p = 0.05;
n = 6). Although these increases in brain IGF-I appear
to be less pronounced than those found by immunocytochemistry (compare
Fig. 2D with Fig. 1A), the latter
technique does not reflect quantitative changes. In addition, brain
IGF-I mRNA levels were not altered by exercise (data not shown).
Uptake of blood-borne IGF-I by neurons follows a time-dependent
pattern. Brain labeling was found 5 min after injection of IGF-I and
remained for several hours (Fig. 2C). Uptake of blood-borne DIG-IGF-I was a saturable process because labeling was completely blocked by simultaneous intracarotid injection of excess unlabeled IGF-I (100 µg per rat) (Fig. 2B). On the contrary,
insulin, a peptide with close structural homology to IGF-I, did not
completely block neuronal labeling even at very high doses (Fig.
2B). Although insulin also enters into the brain
after peripheral administration (Poduslo et al., 1994 ; Reinhardt
and Bondy, 1994 ), the pattern of brain staining after intracarotid
injection of digoxigenin-labeled insulin is different from that
observed after IGF-I and much weaker (data not shown).
We next analyzed possible routes of entry of blood-borne IGF-I into the
brain. Based on previous observations (Fernandez-Galaz et al., 1998 ),
we considered it likely that serum IGF-I enters the brain using the CSF
pathway. We observed that CP epithelial cells, and subsequently
ependymal cells of the ventricular walls, were profusely labeled with
DIG-IGF-I (Fig. 3A). CP cells
show great abundance of IGF-I receptor immunoreactivity (Fig.
3A). When excess unlabeled IGF-I was injected into the CSF
(100 µg per rat), the entry of labeled IGF-I from the blood was
completely blocked (Fig. 3C). When saline was injected
intracerebroventricularly, no blockade was seen (data not shown). More
significant was the observation that levels of IGF-I in the CSF of
animals that received intracarotid injection of 10 µg of IGF-I were
400% higher 15 min after the injection than saline-injected rats
(p < 0.04) (Fig. 3B). Finally,
delivery of labeled IGF-I into the lateral ventricle resulted in
staining of the same brain areas that stained after intracarotid
injection (Fig. 3D).

View larger version (67K):
[in this window]
[in a new window]
|
Figure 3.
Serum IGF-I enters into the brain through the
blood-CSF pathway. A, Epithelial cells of the choroid
plexus (CP) accumulate DIG-IGF-I and show IGF-I
receptor immunoreactivity. a, Digoxigenin labeling of CP
cells in the lateral cerebral ventricle (LV) of a
rat injected with DIG-IGF-I 5 min before. b, Ependymal
cells (EC) lining the wall of the ventricle show
digoxigenin staining 1 hr after injection of DIG-IGF-I.
c, IGF-I receptor immunoreactivity in CP cells.
B, Levels of immunoreactive IGF-I in the CSF were
significantly increased 15 min after intracarotid injection of the
peptide. *p = 0.03 versus saline-injected control
rats by Whitney test (n = 3). C,
Injection of excess unlabeled IGF-I into the CSF displaces the uptake
of serum DIG-IGF-I. Cerebellar Purkinje cells
(a) or IO neurons (c)
stained with DIG-IGF-I 1 hr after intracarotid injection. DIG-IGF-I
staining of Purkinje cells (b) or IO neurons
(d) is absent after intracerebroventricular
injection of 100 µg unlabeled IGF-I. D, The pattern of
neuronal uptake of IGF-I is similar after either
intracerebroventricular (a, b) or
intracarotid injection of DIG-IGF-I (c,
d). Arrows indicate examples of positive
cells. Scale bar, 50 µm. Antibodies that were used are as in previous
figures.
|
|
Blood-borne IGF elicits changes in the electrophysiological
properties of target neurons
What is the functional significance, if any, of the entry of
circulating IGF-I into the brain? Because increased neuronal staining
with c-Fos is associated with neuronal activation (Grassi-Zucconi et
al., 1993 ), and intracarotid injection of IGF-I or exercise each
markedly increased the number of c-Fos-positive neurons, we determined
whether blood-borne IGF-I elicits changes in neuronal activity. We
chose two different areas showing prominent accumulation of serum
IGF-I: the cerebellar cortex and the DCN of the lower brainstem.
Cerebellar Purkinje cells (n = 11) showed a spontaneous firing rate of 7.5 ± 1.79 spikes/sec, which gradually increased after intracarotid injection of IGF-I (10 µg) in 9 of 11 cells tested. The increment was observed 15 min after intracarotid injection of IGF-I (14.1 ± 4.62 spikes/sec) and reached statistical
significance at 30 min (15.4 ± 4.04 spikes/sec; p = 0.049) (Fig. 4A1). In
some cases (n = 4), the increment in firing rate was
observed up to 4 hr after injection of IGF-I. No changes were seen when
saline was injected (Fig. 4A2). Furthermore, IGF-I
induced changes in parallel fiber-evoked potentials. A single stimulus
applied to the cerebellar surface activated parallel fibers and evoked
a well characterized field potential at the level of Purkinje cells (Eccles et al., 1966 ; Malenka and Kocsis, 1982 ). The field potential consisted of a brief negative wave followed by a longer lasting second
negativity (Fig. 4B). The first negative wave is
caused by the current generated by propagating impulses along the
parallel fibers, whereas the second negative wave corresponds to the
monosynaptic activation of Purkinje dendrites (Eccles et al., 1966 ).
IGF-I injection induced an increase in the two components of the evoked field potentials in the nine cases that increased spontaneous activity
after IGF-I (Fig. 4B, trace indicated with
arrowheads). To quantify the changes elicited by IGF-I in
parallel fiber-evoked field potentials, the areas of the first and
second negative waves were measured (Fig. 4C). IGF-I
increased the response area of both negative waves (C1,
C2) 15 min after the injection, although the increments were
longer lasting in the first negative wave (C1). Saline
injections (n = 3) did not elicit changes in evoked field potentials.

View larger version (25K):
[in this window]
[in a new window]
|
Figure 4.
Intracarotid injection of IGF-I elicits
long-lasting electrophysiological changes in cerebellar Purkinje cells.
A1, Increase over time of mean spontaneous activity of
Purkinje cells after intracarotid injection of IGF-I
(n = 11). A2, Control saline
injection did not modify the firing rate over time
(n = 3). B, Evoked field potentials
in the cerebellum after parallel fiber stimulation. Two negative waves
with short latencies were elicited. Arrowheads indicate
the trace showing increased evoked potential 15 min after injection of
IGF-I. C, Mean area of the first
(1) and second (2) negative
waves increase after IGF-I injection (n = 11).
Baseline (control) levels were obtained before
intracarotid injection of IGF-I. *p < 0.05.
|
|
Because DCN cells also accumulate IGF-I (Fig.
5A), we tested whether IGF-I
could change their response properties to natural somatosensory
stimulation. Unit activity was recorded at rest and during stimulation
of the receptive fields. IGF-I injection also induced a significant
increase of the firing rate in 11 of 12 DCN neurons, from 1.8 ± 0.42 to 2.8 ± 0.52 spikes/sec after 15 min
(p = 0.02). One hour later they returned to
control levels (Fig. 5B1). As in the cerebellum, saline
injection (n = 4) did not evoke changes in the firing
rate (Fig. 5B2). IGF-I also increased the sensory responses
of those DCN cells showing increased spontaneous activity after IGF-I
(n = 11) (Fig. 5C). To quantify changes
elicited by IGF-I, evoked spikes per stimulus were measured in the 50 msec time interval after stimulus onset. In control conditions,
somatosensory stimulation evoked a mean of 0.89 ± 0.13 spikes per
stimulus, which increased to 1.6 ± 0.26 spikes per stimulus after
15 min of IGF-I injection (p = 0.01). Changes
elicited by IGF-I in DCN response properties were shorter than in
cerebellar neurons, because 1 hr after injection of IGF-I, levels were
no longer significantly higher than baseline values in DCN cells but
remained significantly elevated in cerebellar cells.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 5.
Intracarotid injection of IGF-I elicits
electrophysiological changes in brainstem DCN neurons.
A, DCN cells show intense IGF-I labeling after
intracarotid injection of IGF-I. Similar IGF-I staining of these
neurons is seen after exercise. Arrow indicates an
IGF-I-accumulating neuron. Scale bar, 50 µm. B1, Mean
spontaneous activity of DCN neurons increases 15-30 min after IGF-I
injection and tends toward baseline levels 1 hr later.
B2, Control saline injection did not modify the firing
rate over time (n = 4). C, PSTHs (20 stimuli) of a representative cuneate nucleus cell before
(1) and after (2) 15 min of
intracarotid injection of IGF-I. The neuron responded to somatosensory
stimulation delivered on the second digit of the hindpaw. Note the
increase in the number of stimulus-evoked spikes after IGF-I.
D, The number of spikes evoked by each somatosensory
stimulus increased over time after injection of IGF-I
(n = 12), indicating increased effectiveness of
sensory stimulation. Control refers to values before injection of
IGF-I. *p < 0.05; **p < 0.01.
|
|
 |
DISCUSSION |
The present results indicate that increased uptake of circulating
IGF-I by brain cells after physical exercise is involved in the effects
of exercise on brain function. These findings also suggest a new
physiological role for blood IGF-I through a novel mechanism that
includes passage of circulating IGF-I into the brain, its accumulation
by specific groups of neurons, stimulation of neuronal expression of
c-Fos and BDNF, and long-lasting changes in neuronal activity. Our
observations may lead to new therapeutic approaches and help explain
previous findings of neuroprotective actions of IGF-I after peripheral
administration (Fernandez et al., 1998 ; Pulford et al., 1999 ).
The observation that circulating growth factors access the brain is not
new (Poduslo et al., 1994 ; Wagner et al., 1999 ). However, the
physiological significance of this finding is obscured by the existence
of the blood-brain barriers (Rubin and Staddon, 1999 ). Nevertheless,
the presence of IGF-I receptors in choroid plexus epithelial cells
(Marks et al., 1991 ) as well as in endothelial cells of brain
capillaries (Frank et al., 1986 ) supports the possibility that IGF-I
enters into the brain by either the blood-CSF or blood-brain interfaces. Our results indicate that the blood-CSF pathway is the
major route used by serum IGF-I to access the brain. Thus, choroid
plexus cells are heavily stained soon after intracarotid injection of
IGF-I, whereas CSF levels of IGF-I increased dramatically after
systemic administration of IGF-I. Furthermore, blockade of the uptake
of serum IGF-I by excess IGF-I in the CSF, and a similar pattern of
uptake after either intracarotid or intracerebroventricular administration, suggests a common route of entry.
Both treadmill running and intracarotid IGF-I induce higher levels of
IGF-I in the brain, whereas serum levels remain unchanged. Because
brain IGF-I mRNA levels do not change, the most likely explanation,
although not the only one, is that increased brain levels are caused by
increased uptake of IGF-I from serum. Because similar findings have
been reported in muscle cells after acute exercise (Eliakina et al.,
1997 ), it is conceivable that serum IGF-I levels remain unaltered after
running because of the increased uptake of circulating IGF-I by target
organs such as muscle and brain. In turn, increased brain uptake may be
caused not only by increased circulating levels of IGF-I but also by
the increased brain blood flow induced by exercise or IGF-I itself
(Crill, 1989 ; Gillespie et al., 1997 ).
Uptake of systemic IGF-I by the brain is biologically relevant because
physical exercise stimulates it. More significant is the
observation that intracarotid injection of IGF-I mimics the effects of
exercise on brain c-Fos and BDNF expression (Iwamoto et al., 1996 ;
Liste et al., 1997 ) and that blockade of the uptake of IGF-I by brain
cells results in blockade of the effects of exercise in the brain as
determined by inhibition of increased c-Fos labeling. Furthermore,
accumulation of peripheral IGF-I by areas involved in motor control,
propioceptive sensations, or metabolic regulation, among others,
suggests that circulating IGF-I activates brain areas that are involved
in adaptive responses to physical exercise.
Only a minority of the cells that accumulate IGF-I after either
exercise or exogenous administration of IGF-I express c-Fos. Thus,
whether brain uptake of IGF-I and neuronal c-Fos expression are related
events remains to be determined. The connectivity pattern of
c-Fos-stained neurons with IGF-I-accumulating neurons includes both
afferent and efferent connections between the two populations of cells
(Table 1). This pattern is found both after exercise and after
exogenous intracarotid injection of IGF-I, supporting the possibility
of orthograde or retrograde signaling between the two populations of
neurons. For example, cerebellar granule cells express c-Fos after
IGF-I uptake by Purkinje cells postsynaptically connected to them.
Changes evoked by IGF-I in neuronal properties, such as
those found in the cerebellar cortex and in DCN neurons, appear to have
a physiological significance. Both types of IGF-I-accumulating neurons
had increased sensitivity to afferent stimulation, together with an increased spontaneous firing rate. Previous results have shown
that IGF-I produces changes in the electrophysiological properties of
neurons through modulation of ion channels (Blair and Marshall, 1997 ).
Other neurotrophic factors also modulate neuronal activity (Thoenen,
1995 ). However, to our knowledge this is the first evidence that IGF-I
directly modulates neuronal activity in vivo. Interestingly,
the time course of the effects of IGF-I on the two types of neurons
that were analyzed is different. Although in DCN neurons the effects of
IGF-I revert in 1 hr, in cerebellar Purkinje cells changes last several
hours. The latter agrees with long-lasting effects of IGF-I on Purkinje
cells (Castro-Alamancos and Torres-Aleman, 1993 ) and suggests that
different mechanisms may underlie these changes. At any rate, changes
produced by IGF-I on ion channels or on as yet undetermined
intracellular targets seem to be of physiological relevance for
regulation of synaptic transmission and firing pattern. Should IGF-I
increase the activity of all target neurons in the brain, and this
remains to be studied, we can envisage a situation in which the level
of activity of many neurons throughout the brain could be potentially
modulated by circulating IGF-I. This is in accordance with the proposed role of volume transmission in the brain, whereby humoral factors present in the blood-CSF-brain interstitial fluid compartment exert
broad modulatory actions in the brain (Zoli et al., 1998 ).
In summary, serum IGF-I enters into the brain through the blood-CSF
pathway and activates different target neurons throughout the brain in
a long-term fashion. Physiological stimuli such as physical exercise
and probably other as yet undetermined stimuli trigger an increased
neuronal uptake of circulating IGF-I that can help explain part of the
effects of exercise on brain function. In addition, the beneficial
effects of physical exercise on recovery of brain function after injury
could also be related to brain uptake of IGF-I because this peptide
exerts powerful neuroprotective effects after peripheral administration
(Fernandez et al., 1998 ; Pulford et al., 1999 ). Our results open a new
avenue of research on the biological significance of circulating growth
factors in the brain.
 |
FOOTNOTES |
Received Oct. 7, 1999; revised Feb. 3, 2000; accepted Feb. 4, 2000.
Correspondence should be addressed to I. Torres-Aleman, Cajal
Institute, CSIC, Avenida Dr. Arce 37, 28002 Madrid, Spain. E-mail: torres{at}cajal.csic.es.
This work was supported by grants from Direccion General de Ciencia y
Tecnologia (PB97-0018) and Comunidad Autonoma de Madrid (08.5/0051.1/98). We are grateful to J. Sancho and C. Bailon for their
expert help. We also thank L. M. Garcia-Segura for his excellent advice, A. Muñoz for providing the BDNF cDNA, and R. Manso for sharing the treadmill machine with us.
 |
REFERENCES |
-
Auletta M,
Nielsen FL,
Gammeltoft S
(1992)
Receptor-mediated endocytosis and degradation of insulin-like growth factor I and II in neonatal rat astrocytes.
J Neurosci Res
31:14-20[Web of Science][Medline].
-
Blair LAC,
Marshall J
(1997)
IGF-I modulates N and L calcium channels in a PI 3-kinase-dependent manner.
Neuron
19:421-429[Web of Science][Medline].
-
Bondy CA,
Werner H,
Roberts CT,
LeRoith D
(1992)
Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II.
Neuroscience
46:909-923[Web of Science][Medline].
-
Busiguina S,
Chowen J,
Argente J,
Torres-Aleman I
(1996)
Specific alterations of the insulin-like growth factor I system in the cerebellum of diabetic rats.
Endocrinology
137:4980-4987[Abstract].
-
Castro-Alamancos CA,
Torres-Aleman I
(1993)
Long-term depression of glutamate-induced gamma aminobutyric acid release in cerebellum by insulin-like growth factor I.
Proc Natl Acad Sci USA
90:7386-7390[Abstract/Free Full Text].
-
Crill WE
(1989)
The milieu of the central nervous system.
In: Text book of physiology (Patton HD,
ed), pp 759-769. Philadelphia: Saunders.
-
Eccles JD,
Llinas R,
Sasaki K
(1966)
Parallel fiber stimulation and responses induced thereby in the Purkinje cells of the cerebellum.
Exp Brain Res
1:17-39[Web of Science][Medline].
-
Eliakina A,
Moromisato M,
Moromisato D,
Brasel JA,
Roberts C,
Cooper DM
(1997)
Increase in muscle IGF-I protein but not IGF-I mRNA after 5 days of endurance training in young rats.
Am J Physiol
273:R1557-1561.
-
Fernandez AM,
Garcia-Estrada J,
Garcia-Segura LM,
Torres-Aleman I
(1997)
Insulin-like growth factor I modulates c-Fos induction and astrocytosis in response to neurotoxic insult.
Neuroscience
76:117-122[Web of Science][Medline].
-
Fernandez AM,
Gonzalez de la Vega A,
Torres-Aleman I
(1998)
Insulin-like growth factor restores motor coordination in a rat model of cerebellar ataxia.
Proc Natl Acad Sci USA
95:1253-1258[Abstract/Free Full Text].
-
Fernandez AM,
Gonzalez de la Vega A,
Planas B,
Torres-Aleman I
(1999)
Neuroprotective actions of peripherally administered insulin-like growth factor I on the injured olivo-cerebellar pathway.
Eur J Neurosci
11:2019-2030[Web of Science][Medline].
-
Fernandez-Galaz MC,
Torres-Aleman I,
Garcia-Segura LM
(1998)
Receptor-mediated internalization of insulin-like growth factor I in neurons and glia of the central nervous system of the adult rat.
Eur J Anat
2:147-158.
-
Ferry RJ,
Katz LE,
Grimberg A,
Cohen P,
Weinzimer SA
(1999)
Cellular actions of insulin-like growth factor binding proteins.
Horm Metab Res
31:192-202[Web of Science][Medline].
-
Frank HJ,
Pardridge WM,
Morris WL,
Rosenfeld RG,
Choi TB
(1986)
Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels.
Diabetes
35:654-661[Abstract].
-
Gillespie CM,
Markel AL,
Martin AA
(1997)
Effects of insulin-like growth factor I and LR3IGF-I on regional blood flow in normal rats.
J Endocrinol
155:351-358[Abstract/Free Full Text].
-
Gomez-Pinilla F,
Dao I,
Vannarith S
(1997)
Physical exercise induces FGF-2 and its mRNA in the hippocampus.
Brain Res
764:1-8[Web of Science][Medline].
-
Grassi-Zucconi G,
Menegazzi M,
Carcereri A,
de Prati A,
Bassetti A,
Montagnese P,
Mandile P,
Cosi C,
Bentivoglio M
(1993)
c-fos mRNA is spontaneously induced in the rat brain during the activity period of the circadian cycle.
Eur J Neurosci
5:1071-1078[Web of Science][Medline].
-
Handelsman DJ,
Spaliviero JA,
Scott CD,
Baxter RC
(1987)
Hormonal regulation of the peripubertal surge of insulin-like growth factor I in the rat.
Endocrinology
120:491-496[Abstract/Free Full Text].
-
Hiney JK,
Srivastava V,
Nyberg CL,
Ojeda SR,
Les Dees W
(1996)
Insulin-like growth factor I of peripheral origin acts centrally to accelerate the initiation of female puberty.
Endocrinology
137:3717-3728[Abstract].
-
Iwamoto GA,
Wappel SM,
Fox GM,
Buetow KA,
Waldrop TG
(1996)
Identification of diencephalic and brainstem cardiorespiratory areas activated during exercise.
Brain Res
726:109-122[Web of Science][Medline].
-
Jones JI,
Clemmons CR
(1995)
Insulin-like growth factors and their binding proteins: biological actions.
Endocr Rev
16:3-34[Abstract/Free Full Text].
-
Liste I,
Guerra MJ,
Caruncho HJ,
Labandeira-Garcia JL
(1997)
Treadmill running induces striatal Fos expression via NMDA glutamate and dopamine receptors.
Exp Brain Res
115:458-468[Web of Science][Medline].
-
Malenka RC,
Kocsis JD
(1982)
Effects of GABA on stimulus-evoked changes in K+ and parallel fiber excitability.
J Neurophysiol
48:608-621[Free Full Text].
-
Marks JL,
Porte D,
Baskin DG
(1991)
Localization of type I insulin-like growth factor receptor messenger RNA in the adult rat brain by in situ hybridization.
Mol Endocrinol
5:1158-1168[Abstract/Free Full Text].
-
Neeper SA,
Gomez-Pinilla F,
Choi J,
Cotman C
(1995)
Exercise and brain neurotrophins.
Nature
373:109[Medline].
-
Paxinos G,
Watson C
(1997)
In: The rat brain in stereotaxic coordinates, Ed 3. Sydney: Academic.
-
Poduslo JF,
Curran GL,
Berg CT
(1994)
Macromolecular permeability across the blood-nerve and blood-brain barriers.
Proc Natl Acad Sci USA
91:5705-5709[Abstract/Free Full Text].
-
Pons S,
Torres-Aleman I
(1992)
Basic fibroblast growth factor modulates insulin-like growth factor I, its receptor and its binding proteins in hypothalamic cultures.
Endocrinology
131:2271-2278[Abstract/Free Full Text].
-
Pulford BE,
Whalen LR,
Ishii DN
(1999)
Peripherally administered insulin-like growth factor I preserves hindlimb reflex and spinal cord noradrenergic circuitry following a central nervous system lesion in rats.
Exp Neurol
159:114-123[Web of Science][Medline].
-
Reinhardt RR,
Bondy CA
(1994)
Insulin-like growth factors cross the blood-brain barrier.
Endocrinology
135:1753-1761[Abstract].
-
Rubin LL,
Staddon JM
(1999)
The cell biology of the blood brain barrier.
Annu Rev Neurosci
22:11-28[Web of Science][Medline].
-
Schwarz AJ,
Brasel JA,
Hintz RL,
Mohan S,
Cooper DM
(1996)
Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF)-I, II, and IGF-binding protein 3 and its proteolysis in young healthy men.
J Clin Endocrinol Metab
81:3492-3497[Abstract].
-
Thoenen H
(1995)
Neurotrophins and neuronal plasticity.
Science
270:593-598[Abstract/Free Full Text].
-
Van Praag H,
Kempermann G,
Gage FH
(1999)
Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus.
Nat Neurosci
2:266-270[Web of Science][Medline].
-
Wagner JP,
Black IB,
DiCicco-Bloom E
(1999)
Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor.
J Neurosci
19:6006-6016[Abstract/Free Full Text].
-
Werther GA,
Abate M,
Hogg A,
Cheesman H,
Oldfield B,
Hards D,
Hudson P,
Power B,
Freed K,
Herington AC
(1990)
Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization: relationship to IGF-I receptors.
Mol Endocrinol
4:773-778[Abstract/Free Full Text].
-
Yakar S,
Liu JL,
Stannard B,
Butler A,
Accili D,
Sauer B,
LeRoith D
(1999)
Normal growth and development in the absence of hepatic insulin-like growth factor I.
Proc Natl Acad Sci USA
96:7324-7329[Abstract/Free Full Text].
-
Zoli M,
Torri C,
Ferrari R,
Jansson A,
Zini I,
Fuxe K,
Agnati LF
(1998)
The emergence of the volume transmission concept.
Brain Res Rev
26:136-147[Medline].
Copyright © 2000 Society for Neuroscience 0270-6474/00/2082926-08$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
P. Rasmussen, P. Brassard, H. Adser, M. V. Pedersen, L. Leick, E. Hart, N. H. Secher, B. K. Pedersen, and H. Pilegaard
Evidence for a release of brain-derived neurotrophic factor from the brain during exercise
Exp Physiol,
October 1, 2009;
94(10):
1062 - 1069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Landi, F. Ciucci, L. Maffei, N. Berardi, and M. C. Cenni
Setting the Pace for Retinal Development: Environmental Enrichment Acts Through Insulin-Like Growth Factor 1 and Brain-Derived Neurotrophic Factor
J. Neurosci.,
September 2, 2009;
29(35):
10809 - 10819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Sév. Deforges, J. Branchu, O. Biondi, C.ém. Grondard, C. Pariset, S. Lécolle, P. Lopes, P.-P. Vidal, C. Chanoine, and F.édér. Charbonnier
Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis
J. Physiol.,
July 15, 2009;
587(14):
3561 - 3572.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Guzzetta, S. Baldini, A. Bancale, L. Baroncelli, F. Ciucci, P. Ghirri, E. Putignano, A. Sale, A. Viegi, N. Berardi, et al.
Massage Accelerates Brain Development and the Maturation of Visual Function
J. Neurosci.,
May 6, 2009;
29(18):
6042 - 6051.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Torres-Aleman
Mouse Models of Alzheimer's Dementia: Current Concepts and New Trends
Endocrinology,
December 1, 2008;
149(12):
5952 - 5957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Laviola, A. Natalicchio, S. Perrini, and F. Giorgino
Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans
Am J Physiol Endocrinol Metab,
November 1, 2008;
295(5):
E991 - E999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Groban, H. Jobe, M. Lin, T. Houle, D. A. Kitzman, and W. Sonntag
Effects of Short-Term Treadmill Exercise Training or Growth Hormone Supplementation on Diastolic Function and Exercise Tolerance in Old Rats
J. Gerontol. A Biol. Sci. Med. Sci.,
September 1, 2008;
63(9):
911 - 920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. N. Ainslie, J. D. Cotter, K. P. George, S. Lucas, C. Murrell, R. Shave, K. N. Thomas, M. J. A. Williams, and G. Atkinson
Elevation in cerebral blood flow velocity with aerobic fitness throughout healthy human ageing
J. Physiol.,
August 15, 2008;
586(16):
4005 - 4010.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson
Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements
J. Neurosci.,
August 22, 2007;
27(34):
9115 - 9129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. McEwen
Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain
Physiol Rev,
July 1, 2007;
87(3):
873 - 904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Gertz, J. Priller, G. Kronenberg, K. B. Fink, B. Winter, H. Schrock, S. Ji, M. Milosevic, C. Harms, M. Bohm, et al.
Physical Activity Improves Long-Term Stroke Outcome via Endothelial Nitric Oxide Synthase-Dependent Augmentation of Neovascularization and Cerebral Blood Flow
Circ. Res.,
November 10, 2006;
99(10):
1132 - 1140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U Shivraj Sohur, J. G Emsley, B. D Mitchell, and J. D Macklis
Adult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells
Phil Trans R Soc B,
September 29, 2006;
361(1473):
1477 - 1497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Svensson, M Diez, J Engel, C Wass, A Tivesten, J-O Jansson, O Isaksson, T Archer, T Hokfelt, and C Ohlsson
Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice.
J. Endocrinol.,
June 1, 2006;
189(3):
617 - 627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Carro, C. Spuch, J. L. Trejo, D. Antequera, and I. Torres-Aleman
Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I
J. Neurosci.,
November 23, 2005;
25(47):
10884 - 10893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Daftary and A. C. Gore
IGF-1 in the Brain as a Regulator of Reproductive Neuroendocrine Function
Experimental Biology and Medicine,
May 1, 2005;
230(5):
292 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ster, C. Colomer, C. Monzo, A. Duvoid-Guillou, F. Moos, G. Alonso, and N. Hussy
Insulin-Like Growth Factor-1 Inhibits Adult Supraoptic Neurons via Complementary Modulation of Mechanoreceptors and Glycine Receptors
J. Neurosci.,
March 2, 2005;
25(9):
2267 - 2276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lopez-Lopez, D. LeRoith, and I. Torres-Aleman
Insulin-like growth factor I is required for vessel remodeling in the adult brain
PNAS,
June 29, 2004;
101(26):
9833 - 9838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Cancedda, E. Putignano, A. Sale, A. Viegi, N. Berardi, and L. Maffei
Acceleration of Visual System Development by Environmental Enrichment
J. Neurosci.,
May 19, 2004;
24(20):
4840 - 4848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Dalsgaard, P. Ott, F. Dela, A. Juul, B. K. Pedersen, J. Warberg, J. Fahrenkrug, and N. H. Secher
The CSF and arterial to internal jugular venous hormonal differences during exercise in humans
Exp Physiol,
May 1, 2004;
89(3):
271 - 277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ehninger and G. Kempermann
Regional Effects of Wheel Running and Environmental Enrichment on Cell Genesis and Microglia Proliferation in the Adult Murine Neocortex
Cereb Cortex,
August 1, 2003;
13(8):
845 - 851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Droste, A. Gesing, S. Ulbricht, M. B. Muller, A. C. E. Linthorst, and J. M. H. M. Reul
Effects of Long-Term Voluntary Exercise on the Mouse Hypothalamic-Pituitary-Adrenocortical Axis
Endocrinology,
July 1, 2003;
144(7):
3012 - 3023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nunez, E. Carro, and I. Torres-Aleman
Insulin-Like Growth Factor I Modifies Electrophysiological Properties of Rat Brain Stem Neurons
J Neurophysiol,
June 1, 2003;
89(6):
3008 - 3017.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Chavez and J. C. LaManna
Activation of Hypoxia-Inducible Factor-1 in the Rat Cerebral Cortex after Transient Global Ischemia: Potential Role of Insulin-Like Growth Factor-1
J. Neurosci.,
October 15, 2002;
22(20):
8922 - 8931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Frago, C. Paneda, S. L. Dickson, A. K. Hewson, J. Argente, and J. A. Chowen
Growth Hormone (GH) and GH-Releasing Peptide-6 Increase Brain Insulin-Like Growth Factor-I Expression and Activate Intracellular Signaling Pathways Involved in Neuroprotection
Endocrinology,
October 1, 2002;
143(10):
4113 - 4122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. W. Booth, M. V. Chakravarthy, S. E. Gordon, and E. E. Spangenburg
Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy
J Appl Physiol,
July 1, 2002;
93(1):
3 - 30.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Duman, J. Malberg, and S. Nakagawa
Regulation of Adult Neurogenesis by Psychotropic Drugs and Stress
J. Pharmacol. Exp. Ther.,
November 1, 2001;
299(2):
401 - 407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. BROADHURST and K. WILSON
Immunology of delirium: new opportunities for treatment and research
The British Journal of Psychiatry,
October 1, 2001;
179(4):
288 - 289.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Carro, J. L. Trejo, S. Busiguina, and I. Torres-Aleman
Circulating Insulin-Like Growth Factor I Mediates the Protective Effects of Physical Exercise against Brain Insults of Different Etiology and Anatomy
J. Neurosci.,
August 1, 2001;
21(15):
5678 - 5684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Trejo, E. Carro, and I. Torres-Aleman
Circulating Insulin-Like Growth Factor I Mediates Exercise-Induced Increases in the Number of New Neurons in the Adult Hippocampus
J. Neurosci.,
March 1, 2001;
21(5):
1628 - 1634.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|